Login to Your Account



NewCo News

Asceneuron Latest Ascension from Merck's Geneva Ashes

By Marie Powers
Staff Writer

Monday, December 3, 2012
The third spin-off from the entrepreneurship partnership program (EPP) launched in April by Merck KGaA biopharmaceutical division Merck Serono SA in conjunction with the closure of its Geneva headquarters, Asceneuron SA is focusing on one of biotech's most elusive targets: Alzheimer's disease (AD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription